Cover Image
市場調查報告書

全球藥物研發市場預測

GLOBAL DRUG DISCOVERY MARKET FORECAST 2018-2026

出版商 Inkwood Research 商品編碼 607157
出版日期 內容資訊 英文 140 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球藥物研發市場預測 GLOBAL DRUG DISCOVERY MARKET FORECAST 2018-2026
出版日期: 2018年02月25日 內容資訊: 英文 140 Pages
簡介

本報告提供全球藥物研發市場相關調查,市場概要,各技術、地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會、課題分析,競爭情形,主要企業的簡介等系統性資訊。

第1章 調查範圍

第2章 調查手法

第3章 摘要整理

  • 市場概要
  • 主要調查結果

第4章 市場決策要素

  • 推動市場要素
  • 市場阻礙因素
  • 市場機會
  • 課題

第5章 全球藥物研發市場:市場區隔

  • 各技術
    • 定量聚合酵素鏈鎖反應(Q-PCR)
    • DNA微陣列
    • 蛋白質微陣列
    • 高通量篩檢(HTS)
    • 質譜分析(MS)
    • 凝膠電泳
    • 層析法
    • 核酸、蛋白質分離
    • 其他技術

第6章 主要分析

  • 波特的五力分析
  • 價值鏈分析
  • PESTEL分析
  • 市場機會的矩陣

第7章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 其他
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 其他
  • 其他地區

第8章 企業簡介

  • ASTRAZENECA PLC
  • BAYER AG
  • BOEHRINGER INGELHEIM
  • ELI LILY
  • F. HOFFMANN-LA ROCHE LTD
  • GLAXOSMITHKLINE LLC
  • JOHNSON AND JOHNSON
  • MERCK & CO. INC.
  • PFIZER, INC.
  • SANOFI

圖表清單

目錄
Product Code: 13150

KEY FINDINGS

Propelled by factors like the low performance of branded drugs as compared to generic drugs and rising spending on healthcare and research, the global drug discovery market is expected to make a leap of 9.73% CAGR, increasing its revenue from $ 36.7 billion to $83.6 billion between the forecast years of 2018-2026.

MARKET INSIGHTS

Technology-wise, the global drug discovery market is segmented into Protein Microarrays, QPCR, Mass Spectrometry, DNA Microarrays, High Throughput Screening, Protein and Nucleic Acid Isolation, Gel Electrophoresis, Chromatography, and Other Technologies. Extensive R&D for new product launches can be viewed as major opportunities for the market to expand.

REGIONAL INSIGHTS

North America, Asia-Pacific, Europe and Rest of World are the geographical segments of this market. By the end of the forecast period, the North American market is anticipated to account for the lion's share of the global market. The U.S is expected to be a major contributor to this region, driven by high healthcare spending and growing lifestyle oriented diseases. Also, the Asia-Pacific market is predicted to register the fastest growth driven by high investments and growing R&D.

COMPETITIVE INSIGHTS

Noted players in the global drug discovery market include Bayer Ag, AstraZeneca Plc, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd, Eli Lily, GlaxoSmithKline Llc, Merck & Co. Inc, Sanofi and Pfizer Inc.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. HIGH PREVALENCE RATES OF MAJOR HEALTH DISORDERS
    • 3.2.2. NORTH AMERICA HAS THE HIGHEST MARKET SHARE
    • 3.2.3. ASIA PACIFIC IS THE FASTEST GROWING REGION
    • 3.2.4. IMPLEMENTATION OF DRUG DISCOVERY PROGRAMS

4. MARKET DETERMINANTS

  • 4.1. MARKET DRIVERS
    • 4.1.1. AGING POPULATION
    • 4.1.2. BRANDED DRUGS ARE OUTPERFORMING DUE TO HIGH COST AS COMPARED TO GENERIC DRUGS
    • 4.1.3. SPENDING ON HEALTHCARE HAS BEEN INCREASING
    • 4.1.4. GLOBAL INCREASE IN LIFESTYLE ORIENTED DISEASES & FATALITIES
  • 4.2. MARKET RESTRAINTS
    • 4.2.1. GOVERNMENT REGULATIONS DELAYING THE PROCESSES
    • 4.2.2. DELAY IN PRODUCT LAUNCHES
    • 4.2.3. POOR ACCESS TO THE HEALTHCARE SERVICES IN DEVELOPING MARKETS
    • 4.2.4. MARKET IS SHIFTING FROM BRANDED TO GENERIC DRUGS
  • 4.3. MARKET CHALLENGES
    • 4.3.1. COST BARRIER FOR LOCAL PEOPLE IN EMERGING ECONOMIES
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. EXTENSIVE R&D FOR NEW PRODUCT LAUNCHES

5. MARKET SEGMENTATION

  • 5.1. MARKET BY TECHNOLOGY 2018-2026
    • 5.1.1. QPCR
    • 5.1.2. DNA MICROARRAYS
    • 5.1.3. PROTEIN MICROARRAYS
    • 5.1.4. HIGH-THROUGHPUT SCREENING
    • 5.1.5. MASS SPECTROMETRY
    • 5.1.6. GEL ELECTROPHORESIS
    • 5.1.7. CHROMATOGRAPHY
    • 5.1.8. PROTEIN AND NUCLEIC ACID ISOLATION
    • 5.1.9. OTHER TECHNOLOGIES

6. KEY ANALYTICS

  • 6.1. PORTER'S FIVE FORCES ANALYSIS
    • 6.1.1. THREATS OF NEW ENTRANTS(LOW)
    • 6.1.2. COMPETITIVE RIVALRY (HIGH)
    • 6.1.3. BARGAINING POWER OF BUYERS (MEDIUM)
    • 6.1.4. BARGAINING POWER OF SUPPLIERS (LOW)
    • 6.1.5. THREAT OF SUBSTITUTE PRODUCTS (HIGH)
  • 6.2. VALUE CHAIN ANALYSIS
  • 6.3. KEY EXCERPTS OF THE STUDY
    • 6.3.1. RELAXATION IN THE REGULATIONS BY THE GOVERNMENT WHICH STOPS RESEARCHERS FROM DOING RESEARCH.
    • 6.3.2. MARKET LEADERS SHOULD OPEN UP THEIR BRANCHES AND RESEARCH LABS IN EMERGING MARKETS.
  • 6.4. PESTLE ANALYSIS
  • 6.5. OPPORTUNITY MATRIX

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. UNITED STATES (U.S.)
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. UNITED KINGDOM (UK)
    • 7.2.2. FRANCE
    • 7.2.3. GERMANY
    • 7.2.4. SPAIN
    • 7.2.5. ITALY
    • 7.2.6. REST OF EUROPE (ROE)
  • 7.3. ASIA PACIFIC
    • 7.3.1. INDIA
    • 7.3.2. CHINA
    • 7.3.3. JAPAN
    • 7.3.4. KOREA
    • 7.3.5. AUSTRALIA
    • 7.3.6. REST OF ASIA-PACIFIC (ROAPAC)
  • 7.4. REST OF THE WORLD (ROW)

8. COMPANY PROFILES

  • 8.1. ASTRAZENECA PLC
    • 8.1.1. COMPANY OVERVIEW
    • 8.1.2. PRODUCT PORTFOLIO
    • 8.1.3. SWOT ANALYSIS
    • 8.1.4. STRATEGIC INITIATIVES
  • 8.2. BAYER AG
    • 8.2.1. COMPANY OVERVIEW
    • 8.2.2. PRODUCT PORTFOLIO
    • 8.2.3. SWOT ANALYSIS
    • 8.2.4. STRATEGIC INITIATIVES
  • 8.3. BOEHRINGER INGELHEIM
    • 8.3.1. COMPANY OVERVIEW
    • 8.3.2. PRODUCT PORTFOLIO
    • 8.3.3. SWOT ANALYSIS
  • 8.4. ELI LILY
    • 8.4.1. COMPANY OVERVIEW
    • 8.4.2. PRODUCT PORTFOLIO
    • 8.4.3. SWOT ANALYSIS
    • 8.4.4. STRATEGIC INITIATIVES
  • 8.5. F. HOFFMANN-LA ROCHE LTD
    • 8.5.1. COMPANY OVERVIEW
    • 8.5.2. PRODUCT PORTFOLIO
    • 8.5.3. SWOT ANALYSIS
    • 8.5.4. STRATEGIC INITIATIVES
  • 8.6. GLAXOSMITHKLINE LLC
    • 8.6.1. COMPANY OVERVIEW
    • 8.6.2. PRODUCT PORTFOLIO
    • 8.6.3. SWOT ANALYSIS
    • 8.6.4. STRATEGIC INITIATIVES
  • 8.7. JOHNSON AND JOHNSON
    • 8.7.1. COMPANY OVERVIEW
    • 8.7.2. PRODUCT PORTFOLIO
    • 8.7.3. SWOT ANALYSIS
    • 8.7.4. STRATEGIC INITIATIVES
  • 8.8. MERCK & CO. INC.
    • 8.8.1. COMPANY OVERVIEW
    • 8.8.2. PRODUCT PORTFOLIO
    • 8.8.3. SWOT ANALYSIS
    • 8.8.4. STRATEGIC INITIATIVES
  • 8.9. PFIZER, INC.
    • 8.9.1. COMPANY OVERVIEW
    • 8.9.2. SWOT ANALYSIS
    • 8.9.3. STRATEGIC INITIATIVES
  • 8.10. SANOFI
    • 8.10.1. COMPANY OVERVIEW
    • 8.10.2. PRODUCT PORTFOLIO
    • 8.10.3. SWOT ANALYSIS
    • 8.10.4. STRATEGIC INITIATIVES

TABLE LIST

  • TABLE 1 GLOBAL DRUG DISCOVERY MARKET BY GEOGRAPHY 2018-2026 (IN $MILLION)
  • TABLE 2 FACT SHEETS OF GLOBAL FATALITIES
  • TABLE 3 GLOBAL DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 4 GLOBAL DRUG DISCOVERY MARKET IN QPCR BY GEOGRAPHY 2018-2026 (IN $MILLION)
  • TABLE 5 GLOBAL DRUG DISCOVERY MARKET IN DNA MICROARRAYS BY GEOGRAPHY 2018-2026 (IN $MILLION)
  • TABLE 6 GLOBAL DRUG DISCOVERY MARKET IN PROTEIN MICROARRAYS, BY GEOGRAPHY 2018-2026(IN $MILLION)
  • TABLE 7 GLOBAL DRUG DISCOVERY MARKET IN HIGH THROUGHPUT SCREENING, BY GEOGRAPHY 2018-2026(IN $MILLION)
  • TABLE 8 GLOBAL DRUG DISCOVERY MARKET IN MASS SPECTROMETRY, BY GEOGRAPHY 2018-2026 (IN $MILLION)
  • TABLE 9 GLOBAL DRUG DISCOVERY MARKET IN GEL ELECTROPHORESIS, BY GEOGRAPHY 2018-2026, (IN $MILLION)
  • TABLE 10 GLOBAL DRUG DISCOVERY MARKET IN CHROMATOGRAPHY, BY GEOGRAPHY 2018-2026 (IN $MILLION)
  • TABLE 11 GLOBAL DRUG DISCOVERY MARKET IN PROTEIN AND NUCLEIC ACID ISOLATION, BY GEOGRAPHY 2018-2026 (IN $MILLION)
  • TABLE 12 GLOBAL DRUG DISCOVERY MARKET IN OTHER TECHNOLOGIES MARKET, BY GEOGRAPHY 2018-2026 (IN $MILLION)
  • TABLE 13 GLOBAL DRUG DISCOVERY MARKET, BY GEOGRAPHY 2018-2026 (IN $MILLION)
  • TABLE 14 NORTH AMERICA DRUG DISCOVERY MARKET, 2018-2026 (IN $ MILLION)
  • TABLE 15 EUROPE DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • TABLE 16 ASIA-PACIFIC DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE LIST
  • FIGURE 1 GLOBAL DRUG DISCOVERY MARKET 2018-2026 (IN $MILLION)
  • FIGURE 2 GLOBAL DRUG DISCOVERY MARKET IN QPCR 2018-2026 (IN $MILLION)
  • FIGURE 3 GLOBAL DRUG DISCOVERY MARKET IN DNA MICROARRAYS 2018-2026 (IN $MILLION)
  • FIGURE 4 GLOBAL DRUG DISCOVERY MARKET IN PROTEIN MICROARRAYS 2018-2026 (IN $MILLION)
  • FIGURE 5 GLOBAL DRUG DISCOVERY MARKET IN HIGH THROUGHPUT SCREENING 2018-2026 (IN $MILLION)
  • FIGURE 6 GLOBAL DRUG DISCOVERY MARKET IN MASS SPECTROMETRY 2018-2026 (IN $MILLION)
  • FIGURE 7 GLOBAL DRUG DISCOVERY MARKET IN GEL ELECTROPHORESIS 2018-2026 (IN $MILLION)
  • FIGURE 8 GLOBAL DRUG DISCOVERY MARKET IN CHROMATOGRAPHY 2018-2026 (IN $MILLION)
  • FIGURE 9 GLOBAL DRUG DISCOVERY MARKET IN PROTEIN AND NUCLEIC ACID ISOLATION 2018-2026 (IN $MILLION)
  • FIGURE 10 GLOBAL DRUG DISCOVERY MARKET IN OTHER TECHNOLOGIES 2018-2026 (IN $MILLION)
  • FIGURE 11 GLOBAL DRUG DISCOVERY MARKET, BY GEOGRAPHY 2018-2026 (IN $MILLION)
  • FIGURE 12 NORTH AMERICA DRUG DISCOVERY MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 13 UNITED STATES DRUG DISCOVERY MARKET, 2018-2026 (IN $ MILLION)
  • FIGURE 14 CANADA DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 15 EUROPE DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 16 UNITED KINGDOM DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 17 FRANCE DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 18 GERMAN DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 19 SPAIN DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 20 ITALY DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 21 REST OF EUROPE (ROE) DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 22 ASIA-PACIFIC DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 23 INDIA DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 24 CHINA DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 25 JAPAN DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 26 KOREA DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 27 AUSTRALIA DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 28 REST OF ASIA-PACIFIC (ROAPAC) DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
  • FIGURE 29 REST OF THE WORLD (ROW) DRUG DISCOVERY MARKET, 2018-2026 (IN $MILLION)
Back to Top